Advanced search
Publication Cover
HIV Clinical Trials Volume 11, 2010 - Issue 5
Submit an article Journal homepage
39
Views
4
CrossRef citations to date
0
Altmetric
Original Articles

Similar Virologic and Immunologic Efficacy With Fosamprenavir Boosted With 100 mg or 200 mg of Ritonavir in HIV-Infected Patients: Results of the LESS Trial

Calvin CohenCommunity Research Initiative of New England Boston, Massachusetts, USA
,
Edwin DeJesusOrlando Immunology Center Orlando, Florida, USA
,
Anthony LaMarcaTherafirst Medical Center Fort Lauderdale, Florida, USA
,
Benjamin YoungUniversity of Colorado, Denver, Colorado, USA
,
Linda YauGlaxoSmithKline Research Triangle Park, North Carolina, USA
,
Lisa PatelGlaxoSmithKline Research Triangle Park, North Carolina, USA
,
Cindy VavroGlaxoSmithKline Research Triangle Park, North Carolina, USA
,
Mary Beth WireGlaxoSmithKline Research Triangle Park, North Carolina, USA
,
Paul WannamakerGlaxoSmithKline Research Triangle Park, North Carolina, USA
&
Mark ShaeferGlaxoSmithKline Research Triangle Park, North Carolina, USACorrespondence[email protected]
 show all
Pages 239-247 | Published online: 06 Jan 2015

REFERENCES

  • Palella F, Delaney K, Moorman A, et al. Declining mor-bidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853–860.
  • Panel on Antiretroviral Guidelines for Adults and Ado-lescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. December 1, 2009: 1-161. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed June 21, 2010.
  • Norvir® [prescribing information]. Abbott Park, IL: Abbott Laboratories; 2010.
  • Shafran S, Mashinter L, Roberts S. The effect of low-dose ritonavir monotherapy on fasting serum lipid concentratri-ons. HIV Med. 2005;6:421–425.
  • US Food and Drug Administration. FDA approves LEXIVA (fosamprenavir calcium). Press release; October 21, 2003.
  • Sadler BM, Piliero PJ, Preston SL, et al. Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers. AIDS. 2001; 15:1009–1018.
  • Ruane PJ, Luber AD, Wire MB, et al. Plasma amprenavir pharmacokinetics and tolerability following administra-tion of 1,400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteers. Antimicrobial Agents Chemother. 2007;51:560–565.
  • Sale M, Sadler BM, Stein DS. Pharmacokinetic modeling and simulations of interaction of amprenavir and ritonavir. Antimicrobial Agents Chemother. 200246: 746–754.
  • Wood R, Eron J, Arasteh K, et al. A 42-week open-label study to assess the pharmacokinetics, antiretroviral activity, and safety of amprenavir or amprenavir plus ritonavir in combination with abacavir and lamivudine for treatment of HIV-infected patients. Clin Infect Dis 2004;39:591–594.
  • Lexiva® [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; 2010.
  • Hirsch MS, Gunthard HF, Schapiro JM, et al. Antiretrovi-ral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society—USA panel. Clin Infect Dis. 2008;47:266–285.
  • Hicks C, DeJesus E, Sloan L, et al. Comparison of once-daily fosamprenavir boosted with either 100 or 200 mg rito-navir, in combination with abacavir/lamivudine: 96-week results from COL100758. AIDS Res Human Retroviruses. 2009;25:395–403.
  • Kurowski M, Walli RK, Breske A, et al. Fosamprenavir/ ritonavir plus tenofovir does not affect amprenavir pharmacokinetics: no effect of tenofovir. AIDS. 2007; 21:1368–1370.
  • Smith KY, Weinberg WG, DeJesus E, et al. Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT. AIDS Res Ther. 2008;5:5.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.